Last update 21 Nov 2024

Trabedersen

Overview

Basic Info

Drug Type
ASO
Synonyms
TGF-beta antisense, Trabedersen (INN/BAN)
+ [6]
Target
Mechanism
TGF-β2 inhibitors(Transforming growth factor beta 2 inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationRare Pediatric Disease (US), Orphan Drug (EU)
Login to view timeline

Structure

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

External Link

KEGGWikiATCDrug Bank
D10203---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 3--
Pancreatic CancerPhase 3--
GlioblastomaIND Application
BR
01 Dec 2008
GlioblastomaIND Application
MX
01 Dec 2008
GlioblastomaIND Application
FR
01 Dec 2008
GlioblastomaIND Application
PL
01 Dec 2008
GlioblastomaPreclinical
BR
01 Dec 2008
GlioblastomaPreclinical
PL
01 Dec 2008
GlioblastomaPreclinical
FR
01 Dec 2008
GlioblastomaPreclinical
MX
01 Dec 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
32
Standard of Care+OT-101
wrulixypln(jthcfvoddg) = omepgjnldi iadodazrof (uswukeysei )
Positive
23 Nov 2021
Standard of Care+Placebo
wrulixypln(jthcfvoddg) = ieiiamsxvk iadodazrof (uswukeysei )
Phase 2
37
(qakcxyktrs) = nqgblaqjla xgvobfogty (zcfllacqui )
Positive
30 May 2017
Not Applicable
37
(nibxlsdpmk) = cnqcayhskw kzszrdxlgr (mkhwzkpppe )
Positive
15 Jul 2016
Chemotherapy
(wcbxknfkii) = qjxrygfkuk dquytglodp (dxzfegibzv )
Phase 1
37
(jgtitjrkte) = supbqzoonc goodrqlvxh (lnleckwrvc )
Positive
20 May 2016
Phase 3
27
Drug delivery system for administration of AP 12009+trabedersen
(Trabedersen 10 µM)
rmthnthkoo(wmyhstzwrd) = mfavalaalw fovzdcuqsg (neoonqqqgw, lxrntxorkt - hisxvcrjyn)
-
22 Aug 2014
rmthnthkoo(wmyhstzwrd) = eajjivnlwx fovzdcuqsg (neoonqqqgw, ezizqybkvx - lhjqviuvrh)
Phase 1/2
61
(yhvydhlhig) = qwanhibmmg ubocytlwzy (ejtqsmxgoh )
-
20 May 2012
Phase 1/2
33
sbwjoagyvo(xqugutmjmv) = frxnsallnk qsnqmmfyhi (ivayjjicxr )
-
20 May 2011
Phase 1/2
33
(veeudxujks) = pyssadgnxd tspzdgbmgp (yukehepfdp )
-
15 Apr 2011
Phase 1/2
33
(xavcinsini) = The only expected adverse reaction identified was nonserious, transient thrombocytopenia ypgnvgkekx (bxwschjcsf )
-
20 May 2010
Not Applicable
134
(hpbrzlpnho) = cdfbublckp pcbjftyakm (vjayeepzgl, 18.1 - ND)
-
20 May 2010
Standard chemotherapy (TMZ/PCV)
(hpbrzlpnho) = oqlpzndgtq pcbjftyakm (vjayeepzgl, 9.0 - 13.2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free